Denali Therapeutics Inc. (DNLI) - What Are Analysts Saying About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Sixteen analysts rate Denali Therapeutics a consensus “Moderate Buy,” including 13 buys, two holds and one sell. The average 12-month price target is $35.85, well above the reported $18.68 share price.
• Recent financial results were mixed: Denali reported quarterly revenue of $3.60 million, exceeding expectations, but its $0.68 per-share loss was wider than the anticipated $0.51 loss. Analysts expect a full-year loss of approximately $2.60 per share.
• Institutional ownership is substantial: Institutional investors and hedge funds own 92.92% of the stock, with BlackRock recently acquiring a stake valued at roughly $360.8 million. An insider also sold 2,768 shares under a pre-arranged trading plan.

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have been assigned an average rating of "Moderate Buy" from the sixteen analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and thirteen have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $35.85.

Several research analysts have recently commented on the company. B. Riley Financial raised their price target on Denali Therapeutics from $30.00 to $35.00 and gave the stock a "buy" rating in a research report on Tuesday, August 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Denali Therapeutics in a report on Thursday, October 15th. Wedbush reaffirmed an "outperform" rating and set a $26.00 price objective on shares of Denali Therapeutics in a research report on Monday, July 13th. Wall Street Zen downgraded shares of Denali Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, October 10th. Finally, JPMorgan Chase & Co. assumed coverage on Denali Therapeutics in a research report on Monday, July 13th. They set an "overweight" rating and a $29.00 price target on the stock.

Denali Therapeutics Trading Down 1.3%

DNLI opened at $18.68 on Thursday. The stock has a market capitalization of $2.99 billion, a PE ratio of -6.58 and a beta of 1.02. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. Denali Therapeutics has a one year low of $13.75 and a one year high of $27.30. The business's 50 day moving average price is $21.41 and its 200 day moving average price is $21.75.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million during the quarter, compared to analysts' expectations of $2.15 million. During the same period last year, the firm earned ($0.72) earnings per share. As a group, equities research analysts expect that Denali Therapeutics will post -2.60 EPS for the current year.

Insider Buying and Selling

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,768 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $23.44, for a total transaction of $64,881.92. Following the completion of the sale, the insider directly owned 278,995 shares of the company's stock, valued at approximately $6,539,642.80. This trade represents a 0.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Denali Therapeutics

Several hedge funds have recently made changes to their positions in DNLI. BlackRock Inc. acquired a new stake in Denali Therapeutics in the second quarter valued at about $360,759,000. Dimensional Fund Advisors LP increased its holdings in Denali Therapeutics by 13.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company's stock valued at $51,687,000 after acquiring an additional 317,872 shares in the last quarter. Pictet Asset Management Holding SA raised its position in shares of Denali Therapeutics by 92.5% during the 1st quarter. Pictet Asset Management Holding SA now owns 2,558,865 shares of the company's stock worth $48,439,000 after purchasing an additional 1,229,757 shares during the last quarter. ADAR1 Capital Management LLC lifted its position in shares of Denali Therapeutics by 3,490.9% in the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company's stock valued at $35,932,000 after acquiring an additional 1,819,339 shares in the last quarter. Finally, Defilade Capital Management L.P. boosted its stake in shares of Denali Therapeutics by 107.1% during the 1st quarter. Defilade Capital Management L.P. now owns 1,359,969 shares of the company's stock worth $26,111,000 after purchasing an additional 703,256 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company's research programs target conditions including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.